Published • loading... • Updated
Insilico Medicine And SK Biopharmaceuticals Achieved AI-Powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
The partnership could reach $2.5 billion and combines Insilico's AI platform with SK Biopharmaceuticals' late-stage development and commercialization expertise.
- On Monday, June 22, 2026, Insilico Medicine and SK Biopharmaceuticals announced a research collaboration at the BIO 2026 International Convention to discover AI-enabled drug candidates for neuroimmune disorders.
- The partnership unites Insilico's AI-driven target-to-candidate engine with SK Biopharmaceuticals' deep CNS mastery, targeting disorders with historically low clinical success rates and significant unmet patient need.
- Insilico will receive up to $18 million in upfront payments, with total potential deal value exceeding $2.5 billion; the company reaches preclinical candidate nomination in 12 to 18 months versus 2.5 to 4 years traditionally.
- SK Biopharmaceuticals will steer late-stage development and commercialization for all resulting programs, building on its successful development of the epilepsy treatment Cenobamate in the United States.
- Dr. Alex Zhavoronkov, founder, co-CEO, and CBO of Insilico Medicine, stated the collaboration "underscores the tremendous power of industry communication" and sets a new standard for efficient preclinical drug development.
Insights by Ground AI
23 Articles
23 Articles
keenesentinel.com+21 Reposted by 21 other sources
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide,…
Coverage Details
Total News Sources23
Leaning Left6Leaning Right2Center6Last UpdatedBias Distribution43% Left, 43% Center
Bias Distribution
- 43% of the sources lean Left, 43% of the sources are Center
43% Center
L 43%
C 43%
14%
Factuality
To view factuality data please Upgrade to Premium
